Writing for Regulatory Agencies vs. Medical Journals: The Differences

When a clinical trial is completed, regardless of the outcome, the results need to be shared. From a regulatory perspective, they have to be shared.
On the other hand, from the perspective of disseminating information throughout the scientific community, researchers may decide they want to share the information to a broader audience. The best avenue for this is publication in a scientific journal.
For a medical writer, these are two very different tasks.
Who are you writing for?
Regulatory writing is highly standardized and requires rigid adherence to the guidelines developed by the agencies governing the review and approval process. In addition to these guidelines, companies have our own standard operating procedures (SOPs) that ensure compliance at every step of the clinical trial reporting process and harmonization across various clinical trial programs.
The end result is a very thorough, detailed, and complete presentation of the entire clinical trial, from inception at the protocol level, to completion with final data.
The final report that is produced – a Clinical Study Report – can be very lengthy, many times exceeding one hundred pages or more. It is a dense, detailed, and intricate document, with a purpose to provide a full account of the conduct and outcome of the clinical trial. The regulatory agencies, by design, will have everything they need.
Communicating the important, possibly critical, findings from a clinical trial to other researchers and interested parties must expand beyond the clinical study report. A brief summary that captures the salient ‘take home’ messages of the outcomes can reach a large audience through professional journals.
In fact, journal publication is quite often part of a study sponsor’s strategy for wider visibility of their clinical trial. This is where the approach to reporting diverges.
Writing for medical journals
There are many choices with regards to journals, and each one has unique requirements. Once the most appropriate journal to reach the sponsor’s target audience has been selected, it becomes necessary to determine how best to structure the study results to the journal’s specific format.
There is no one size fits all approach to journal publication. Each journal has its own unique set of specifications for structure, length, and presentation.
Apart from the limitations for word count, number of allowed tables or figures, and other more cosmetic attributes, there is a decidedly different approach needed for the data presentation. Journal articles can be thought of more as a big picture document. Substantiating data needs to be presented, but in a truncated format. Additionally, the emphasis on how the data was acquired, how it was analyzed, and what it means, tends to be favored over discussion of the preliminaries as provided in a clinical study report.
Getting the abstract right
The abstract, which is generally required for journal articles of all types, is one of the most critical components. Sometimes, abstracts can be limited to as few as 150 words.
In that small space, the abstract must convey the design, conduct, and outcome of the clinical study concisely and accurately. For much of the journal’s reading audience, the abstract may be the only part of the article that is read, and it will be vital for making the article searchable.
Whether writing a clinical study report or a journal article, both illustrate the summarization of clinical trial data, serving multiple functions. Regardless of formatting, structure, and organizational limitations, medical writers are tasked with the ultimate goal of communicating complex data clearly and accurately. This in turn contributes to the knowledge base that ultimately furthers research – in all its forms.
by Megan Day, AA, BA, PhD (ABD)
About the author
Megan Day, AA, BA, PhD (ABD) is a Senior Medical Writer on the MMS European writing team, based in Dublin, Ireland.
Suggested For You

perspectives
July 16th, 2024
Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives
June 21st, 2024
Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives
April 19th, 2024
The Emerging Role of Artificial Intelligence (AI) in Global Medical Writing

perspectives
November 2nd, 2023
Comparability Studies for Biologics: What Drug Developers Need to Succeed

perspectives
October 11th, 2023
Understanding the Revised Draft Guidance for Formal Meetings with the FDA

perspectives
August 16th, 2023
Automatiqc®: Bridging the Gap Between AI Precision and Human Expertise in Medical Writing and Quality Control

perspectives
July 6th, 2023
3 Tips for CSR Writing: Best Practices for Lean and Effective Clinical Study Report Writing

perspectives
April 6th, 2023
A Reflection on My Medical Writing Career: The Art of Mentoring

perspectives
June 14th, 2022
Medical Writing Trends in the Era of COVID-19 and Remote Work: Enhancing Virtual Relationships and Emphasizing Emotional Intelligence

perspectives
March 24th, 2022
How to Succeed in the Pharma Industry: Conversations with Instructors at MMS Academy Part 1

perspectives
December 1st, 2021
FDA Expedited Program Designations to Support Rare Disease Drug Development

perspectives
October 8th, 2021
How to use a Master Protocol to gain Efficiencies in a Clinical Trial